BFC Planning’s Crinetics Pharmaceuticals CRNX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-79
Closed -$2.96K – 3494
2026
Q2
$2.96K Buy
79
+17
+27% +$632 ﹤0.01% 2879
2026
Q1
$2.25K Hold
62
– – ﹤0.01% 2561
2025
Q4
$2.89K Hold
62
– – ﹤0.01% 2525
2025
Q3
$2.58K Buy
+62
New +$1.98K ﹤0.01% 2403
2025
Q2
– Sell
-50
Closed -$1.68K – 2708
2025
Q1
$1.68K Hold
50
– – ﹤0.01% 2340
2024
Q4
$2.56K Hold
50
– – ﹤0.01% 2222
2024
Q3
$2.56K Buy
+50
New +$2.58K ﹤0.01% 2215

Other funds holding CRNX

BFC Planning's CRNX Position: Q3 2026 in Review

BFC Planning sold out of Crinetics Pharmaceuticals (CRNX) in Q3 2026, closing a stake of 79 shares — an estimated $2.96K sold.

BFC Planning first reported a position in CRNX in Q3 2024 and held it in 7 quarters. The position peaked at $2.96K in Q2 2026. 2 funds tracked by Wall St. Rank hold CRNX as of Q3 2026.

  • BFC Planning reported no remaining Crinetics Pharmaceuticals position as of Q3 2026 after selling out during the quarter.
  • BFC Planning sold 79 Crinetics Pharmaceuticals shares in Q3 2026, an estimated $2.96K.
  • BFC Planning first reported a position in Crinetics Pharmaceuticals in Q3 2024 and held it in 7 quarters.
  • BFC Planning's Crinetics Pharmaceuticals position peaked at $2.96K in Q2 2026.
  • 2 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q3 2026.

Based on BFC Planning's 13F filing for Q3 2026, filed 13 Nov 2026.